Abstract
The management and outcomes of patients with thymoma-associated myasthenia gravis (TAMG) are heterogeneous. Here, the authors propose a novel classification system based on Masaoka stage and Myasthenia Gravis Foundation of America (MGFA) classification, aiming to guide surgical decisions and perioperative management for these patients. Considering both oncological and neurological factors, this novel TAMG classification provides valuable information on outcome stratification and clinical decision-making for TAMG.